Effectiveness and safety of bronchial thermoplasty in the treatment with severe persistent bronchial asthma
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-UMIN000018140
- Lead Sponsor
- Department of Respiratory Medicine, National Center for Global Health and Medicine
- Brief Summary
Asthma-related Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnaire (ACQ)-5 scores were improved at both 1 and 12 months after BT. Mean FEV1 was increased at 1 and 12 months. The mean annual number of severe exacerbations requiring systemic corticosteroids decreased from 5.8 to 2.0 at 12 months after BT. No serious adverse event was observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Not provided
1.Have a pacemaker, internal defibrillator, or other implantable electronic device. 2.Have a known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, and benzodiazepines. 3.Have been previously treated with BT 4.Active respiratory infection 5.Asthma exacerbation or changing dose of systemic corticosteroids for asthma (up or down) in the past 14 days 6.Known coagulopathy. As with other bronchoscopic procedures, patients should stop taking anticoagulants, antiplatelet agents, aspirin, and NSAIDS before the procedure with physician guidance
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method